GlassScriptPhysician profile
Bradley J Palmer
NPI 1982635207
$4,149.99
in general payments reported to CMS, 2019-2025
31 companies · $973 in 2025
The $973 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $1,031 · 2023: $947 · 2024: $994 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $774.71 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $384.46 | 2022-2025 | |
| Novo Nordisk INC | $301.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $228.96 | 2021-2024 | |
| Lilly USA, LLC | $224.44 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $158.16 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $157.28 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $92.69 | 2022-2023 | Repatha |
| Antares Pharma, INC. | $85.50 | 2021-2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $62.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $61.56 | 2022-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $59.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.31 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Ardelyx, INC. | $54.20 | 2024-2025 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $48.88 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $44.95 | 2022-2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $43.67 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $41.33 | 2025 | Rexulti |
| Ibsa Pharma INC. | $40.75 | 2023-2024 | Tirosint, Licart, Tirosint |
| Shield Therapeutics INC | $36.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.35 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.85 | 2025 | Caplyta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.06 | 2022 | |
| Procept Biorobotics Corporation | $20.01 | 2024 | Aquabeam System |
| Exeltis, USA INC. | $19.95 | 2023 | Slynd |
| Idorsia Pharmaceuticals US INC | $18.36 | 2023 | Quviviq |
| Dexcom, INC. | $16.69 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $15.75 | 2024 | Cologuard Collection Kit |
| Tolmar, INC. | $14.40 | 2024 | |
| Endogastric Solutions, INC | $9.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.